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Schizophrenia, the most severe form of psychopathology,
affects about 1% in the general population. Cognitive
impairment is a central feature of this illness. Most
patients have a poor functional outcome, including defi-
cits in social, occupational, and self-care activities. It is the
most expensive psychiatric disorder to treat. The cost
borne by the society in terms of social welfare administra-
tion and criminal justice, the time spent by unpaid car-
egivers, and the great loss of productivity due to the illness
itself, are perhaps greater than the direct costs, such as,
hospitalization. Functional deficits in schizophrenia are
most strongly predicted by the current severity of cogni-
tive impairment, followed by the severity of negative
symptoms. Severity of positive symptoms is not strongly
associated with the level of functional impairments, even
in those with very poor outcome schizophrenia. There is
thus an urgent need to find strategies for improving cog-
nitive functioning in schizophrenia. It is widely felt by cli-
nicians that conventional antipsychotic drugs have potent
therapeutic actions on psychotic positive symptoms, but
relatively weak actions on negative or cognitive symp-
toms. Atypical antipsychotics have been found to have
greater effects on cognitive and negative symptoms than
conventional antipsychotics, thus showing promise for
cognitive enhancement and thus improved outcome of
this illness possibly a result which may be due to the
effects of 5HT and other neurotransmitter systems and
normalisation of dopamine function by these com-
pounds. Social cognition and learning are probably the
domains most likely to have relevance to functional out-
come. Facilitation of central cholinergic activity may form
another potential treatment strategy for cognitive impair-
ment in this population, since lesion and pharmacologi-
cal studies in experimental animals and pharmacological
probe studies in normal volunteers have repeatedly dem-
onstrated a relationship between central cholinergic activ-
ity and cognitive functions, such as learning, memory and
attention. Functional MRI (fMRI) is a non-invasive tech-
nique with good temporal and spatial resolution. It
requires no radioactivity and offers the ability to map,
almost in real-time, the physiological events occurring in
the brain. fMRI can be used as a tool to map the longitu-
dinal effects of antipsychotic drugs on the brain in schiz-
ophrenia. It allows us to carry out repeated measurements
of cerebral neuronal activity and to investigate functional
changes in the brain in treatment responders and non
responders. It is thus possible to map the functional anat-
omy of neurocognitive improvement with atypical antip-
sychotics in schizophrenia. This presentation will outline
new methods of brain imaging and how these methods
may allow us to understand the long-term effects of cog-
nitive improvement with antipsychotic drugs in schizo-
phrenia
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